Tenosynovial Giant Cell Tumor Treatment Market Size, Share, Industry, Forecast and outlook (2024-2031)

Global Tenosynovial Giant Cell Tumor Treatment Market is segmented By Disease Type (Localized Giant Cell Tumor, Diffuse Giant Cell Tumor), By Treatment Type (Drug Therapy, Radiation Therapy, Surgical Procedures), By End-use (Hospital, Surgical Clinics), and By Region (North America, South America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031

Report Overview

Global Tenosynovial Giant Cell Tumor Treatment Market is expected to grow at a CAGR of 4.2% during the forecast period 2024-2031.

Tenosynovial giant cell tumors refer to rare, benign lesions involving synovial joints, tendon sheaths, and adjacent soft tissues. As these are benign, they cannot cause cancer; however, they can multiply themselves and cause damage to the tissue surrounding the lesion. It mainly affects individuals aged between 25 and 40 years, with a median age of diagnosis being around 30.

Surgery is one of the major options adopted for the treatment of tenosynovial giant cell tumors. In 2019, the FDA approved tyrosine kinase inhibitor Turalio (pexidartinib) to treat adult patients with symptomatic tenosynovial giant cell tumors and not amenable to a certain improvement surgery. There is a range of drugs that have been studied for the treatment of tenosynovial giant cell tumors. According to the National Organization for Rare Disorders, several medications have the potential to block the CSF-1 receptor activities, which were studied for the treatment of tenosynovial giant cell tumors in 2017.

Tenosynovial Giant Cell Tumor Treatment Market Summary

For More Insights Request Free Sample

Tenosynovial Giant Cell Tumor Treatment Market Dynamics

The global tenosynovial giant cell tumor treatment drugs market growth is driven by the rising prevalence of tenosynovial giant cell tumors and the continuous advancement in medication and surgical procedures.

The increasing incidence of tenosynovial giant cell tumors is driving market growth.

The tenosynovial giant cell tumor treatment market is primarily driven by the rising incidence of tenosynovial giant cell tumors and the rising awareness regarding the tumor in developed and emerging economies, such as the UK, the US, Germany, and others. According to the National Organization for Rare Disorders, the incidence rate of tenosynovial giant cell tumors is estimated to be 1.8 people in a population base of one million people. The diagnosis of tenosynovial giant cell tumors is continuously increasing globally, emphasizing the tenosynovial giant cell tumor.

Improvement in the diagnosis and treatment of tenosynovial giant cell tumors is expected to drive market growth.

The increasing incidence of tenosynovial giant cell tumors leads to the development of effective diagnosis and treatment facilities in developed and emerging nations across the globe. The research institutes and pharmaceutical companies focus on developing novel medication and surgical treatments for tenosynovial giant cell tumors.

A specialized imaging technique, MRI (magnetic resonance imaging), is often used to diagnose a tenosynovial giant cell tumor. A physician or doctor takes a synovial fluid sample, which indicates the occurrence or possible development of a tenosynovial giant cell tumor. With people suffering from tenosynovial giant cell tumors, the synovial fluid often detects blood in the sample. However, in certain cases, the microscopic examination or surgical removal of affected tissue is needed to confirm the occurrence of a tenosynovial giant cell tumor.

Lack of awareness and high cost of treatment procedures is likely to hinder the market growth.

On the contrary, the lack of awareness regarding the tenosynovial giant cell tumor in underdeveloped economies and the high cost of treatment procedure for the tenosynovial giant cell tumor during the forecast period.

COVID-19 Impact on Tenosynovial Giant Cell Tumor Treatment Market

The COVID-19 pandemic outbreak will harm the growth of the tenosynovial giant cell tumor market in 2020. The shift in focus of the research institutes and the pharmaceutical and biotechnology companies towards developing effective treatment solutions for COVID-19 has derailed tenosynovial giant cell tumor treatment progress. Moreover, the decline in the number of diagnostic procedures amidst the pandemic hampered the tenosynovial giant cell tumor treatment market's market value in 2020. Therefore, a modest decline in the tenosynovial giant cell tumor market is estimated in 2020; however, the market is expected to regain growth in the third quarter of 2021.

Tenosynovial Giant Cell Tumor Treatment Market Segmentation Analysis

The tenosynovial giant cell tumor treatment market is classified into drug therapy, radiation therapy, and surgical procedures by treatment type.

The surgical procedures segment is expected to grow at the fastest CAGR during the forecast period (2020-2027)  

The surgical procedures segment is expected to maintain its dominance throughout the forecast period. Surgical procedures are often practised for the diagnosis and treatment of tenosynovial giant cell tumors. In severe cases of tenosynovial giant cell tumor, where MRI cannot deduce the result or offer a confirmation receipt regarding the occurrence of tenosynovial giant cell tumor in an individual, surgical procedures are performed. A biopsy of affected tissue is studied through surgery to confirm the incidence of tenosynovial giant cell tumor. Likewise, surgical procedures are often performed in the treatment of tenosynovial giant cell tumors. Pigmented villonodular synovitis slowly revises itself, which leads to recurrence post-surgery.

Based on end-use, the tenosynovial giant cell tumor treatment market is bifurcated into hospitals and surgical centres.

The hospitals are expected to dominate the tenosynovial giant cell tumor treatment market during the forecast period.

These hospitals are the prime destination considered by an individual to diagnose and treat tenosynovial giant cell tumors. The presence of several advanced hospitals equipped with advanced facilities increases patient visits across the globe. Moreover, the hospital's post-surgical procedures' proper treatment facilities and care further attract the patients to treat tenosynovial giant cell tumors.

Global Tenosynovial Giant Cell Tumor Treatment Market Geographical Share

North America region holds the largest market share in the global Tenosynovial Giant Cell Tumor Treatment market.

The North American region dominated the global tenosynovial giant cell tumor treatment market and accounted for the largest market share in 2019. The well-developed healthcare infrastructure and key market players, such as Deciphera Pharmaceuticals, Inc. and Five Prime Therapeutics, Inc., are factors driving the region's market growth. In North America, the US is expected to lead the regional market owing to heavy investment from the manufacturers and government direct investment.

Tenosynovial Giant Cell Tumor Treatment Companies and Competitive Landscape

The tenosynovial giant cell tumor treatment market is moderately competitive, with the presence of global companies.  The key players contributing to the market's growth include Celleron Therapeutics, Daiichi Sankyo, Inc., Ltd, Deciphera Pharmaceuticals, Inc., Five Prime Therapeutics, Inc., Roche Holding AG, among others. The key players are adopting various growth strategies, such as acquisitions, product launches, and collaborations, contributing to the growth of the tenosynovial giant cell tumor treatment market globally.    

Celleron Therapeutics Plc.

Overview: Celleron Therapeutics is a biopharmaceutical company headquartered in Oxford Science Park, UK. The company is engaged in advancing a clinical and pre-clinical pipeline of precision therapies for various cancer indications. It has built a proprietary platform over immune modulation and epigenetic control, providing its drugs with a two-pronged cancer attack. The company is majorly focusing on those cancers where the development of medications and other disease control and treatment procedures are unmet, including tenosynovial giant cell tumor.

Product Portfolio: The Company’s portfolio in the tenosynovial giant cell tumor treatment market comprises emactuzumab.

Key Development: In August 2020, Celleron Therapeutics announced a licensing agreement with Roche Holding AG. Under this agreement, Roche will provide Celleron with global rights for the clinical development, manufacturing, and marketing of emactuzumab. This is expected to improve the treatment of individuals dealing with tenosynovial giant cell tumors, which, in turn, will support the growth of the company in the tenosynovial giant cell tumor market.